PD1 was originally discovered in 1992 as a molecule associated with activation-induced cell
death in T cells. Over the past 30 years, it was found that PD1 has a critical role in avoiding …

Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …

Programmed death-ligand 1 (PD-L1) is a specialized shield on tumor cells that evades the
immune system. Even inhibited by PD-L1 antibodies, a cycling process constantly transports …

Proteolysis targeting chimeras (PROTACs) technology is an emerging approach to degrade
disease‐associated proteins. Here, we report carbon‐dot (CD)‐based PROTACs (CDTACs) …

Targeting programmed cell death protein ligand 1 (PD-L1) remains one of the most essential
immunotherapies in cancer,. PD-L1 has been detected in the nucleus in multiple …

Immunotherapy has achieved great success recently and opened a new avenue for anti-
tumor treatment. Programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) …

Lung cancer accounts for the main proportion of malignancy-related deaths and most
patients are diagnosed at an advanced stage. Immunotherapy and targeted therapy have …

Induction of immunogenic cell death (ICD) in tumor combined with immune checkpoint
blockade (ICB) therapy is widely developed to improve the efficacy of cancer …

PD-1 (Programmed Cell Death Protein-1) and PD-L1 (Programmed Cell Death Ligand-1)
play a crucial role in regulating the immune system and preventing autoimmunity. Cancer …

Understanding the regulatory mechanisms of PD-L1 expression in tumors provides key
clues for improving immune checkpoint blockade efficacy or developing novel …